2024
EV016/#559 Preclinical activity of datopotamab deruxtecan, a novel trophoblast cell-surface antigen 2 (TROP2) directed antibody-drug conjugate targeting TROP2 in high grade serous ovarian carcinoma
Mcnamara B, Greenman M, Bellone S, Demirkiran C, Mutlu L, Hartwich T, Yang-Hartwich Y, Ratner E, Schwartz P, Santin A. EV016/#559 Preclinical activity of datopotamab deruxtecan, a novel trophoblast cell-surface antigen 2 (TROP2) directed antibody-drug conjugate targeting TROP2 in high grade serous ovarian carcinoma. 2024, a91.2-a91. DOI: 10.1136/ijgc-2024-igcs.135.Peer-Reviewed Original Research
2020
Ovarian BDNF promotes survival, migration, and attachment of tumor precursors originated from p53 mutant fallopian tube epithelial cells
Kang M, Chong KY, Hartwich TMP, Bi F, Witham AK, Patrick D, Morrisson MJ, Cady SL, Cerchia AP, Kelk D, Liu Y, Nucci J, Madarikan O, Ueno D, Shuch BM, Yang-Hartwich Y. Ovarian BDNF promotes survival, migration, and attachment of tumor precursors originated from p53 mutant fallopian tube epithelial cells. Oncogenesis 2020, 9: 55. PMID: 32471985, PMCID: PMC7260207, DOI: 10.1038/s41389-020-0243-y.Peer-Reviewed Original ResearchHigh-grade serous ovarian carcinomaBrain-derived neurotrophic factorFallopian tube epitheliumFTE cellsTumor precursorsPathophysiological processesTropomyosin receptor kinase BFallopian tube epithelial cellsBDNF/TrkBReceptor kinase BLethal gynecological malignancyGenetic alterationsSerous ovarian carcinomaFunction mutationsCommon TP53Gynecological malignanciesNeurotrophic factorFallopian tubeOvarian carcinomaRisk factorsFollicular fluidMutant p53 proteinVivo modelTP53 lossEpithelial cells